Damora Therapeutics, Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Damora Therapeutics converted from a Delaware corporation to a Cayman Islands exempted company effective July 16, 2026, with all share classes (Ordinary, Series A/B/C Preferred) converting 1:1. The conversion was approved by the board on December 13, 2025, and by shareholders on February 9, 2026. Three series of non-voting convertible preferred shares (200 Series A, 16,366 Series B, 43,882 Series C shares) were designated with 1,000:1 conversion ratios to ordinary shares and beneficial ownership limitations ranging from 4.9% to 19.99%.
Why this rating
Jurisdictional reincorporation is routine corporate mechanics for small public companies. No dollar amounts, business changes, or asset transfers disclosed. Relative to $4.4M market cap, this is administrative reorganization without financial impact.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.